title: [Mechanisms of organ failure following cardiopulmonary bypass--preventive effects of Ca2+ blocker (nicardipine)].
abstract: The causes of organ failure following cardiopulmonary bypass (CPB) were multi-factorial. Damage was initiated by elastase which was released from activated granulocytes under conditions of significant reduction in the protease inhibitor level (p < 0.01). The increase in endothelin excretion observed during and after the CPB induced a further vasoconstrictive response in the microvasculature and accelerated ischemic cellular damage. Upon completion of the CPB, the elevation of the lysosomal enzyme beta-glucuronidase was influenced by the elastase and endothelin concentrations (r = 0.8 and r = 0.67 respectively). Renal damage, which was detected by an increase in renal tubular enzymes (N-acetyl-beta-D-glucosaminidase and gamma-glutamyltranspeptidase), was affected by endothelin (r = 0.61, 0.75) and elastase concentrations (r = 0.74, 0.75) respectively. In the group treated with nicardipine during the CPB, an increase in beta-glucuronidase was significantly low (p < 0.01) and renal tubular damage was significantly reduced. Moreover, lesser elevation of the elastase level on arrival in the ICU was evidenced (p < 0.05). Thus we concluded that nicardipine inhibited the release of elastase from the activated neutrophils and prevented the vasoconstriction caused by the endothelin secretion.
authors: Department of Cardiovascular Surgery, Jikei University School of Medicine, Tokyo, Japan.
authors: K
authors: K
authors: Hashimoto
authors: K
authors: K
authors: Nomura
authors: K
authors: K
authors: Suzuki
authors: H
authors: H
authors: Okuyama
authors: H
authors: H
authors: Kurosawa
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D016232:Endothelins / Q000097:blood; D005112:Extracorporeal Circulation / Q000009:adverse effects; D006098:Granulocytes / Q000201:enzymology; D006801:Humans; D009529:Nicardipine / Q000494:pharmacology / Q000627:therapeutic use; D010196:Pancreatic Elastase / Q000097:blood
chemical_list: D002121:Calcium Channel Blockers; D016232:Endothelins; D009529:Nicardipine; D010196:Pancreatic Elastase